Innovent Biologics announced today that its total revenue for the first half of 2026 reached RMB 8.618 billion, a year-on-year increase of 44.8%. Boosted by this news, the company's share price in Hong Kong stocks morning trading once surged over 12%, and the Hang Seng Biotech Index rose over 3%. Previously, JPMorgan Chase increased its holdings in Innovent Biologics by 2.355 million shares on August 20, involving HKD 241 million; Morgan Stanley and Goldman Sachs also raised the company's target price on August 19 and August 6, respectively, and Nomura analysts pointed out that the company's net profit exceeded expectations.